Multivitamin Dosage Regimens in the Prevention of Adverse Pregnancy Outcomes Among HIV-Positive Women
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
The purpose of this study is to examine effects of daily administration of multivitamin supplements at doses resembling the Recommended Dietary Allowance (RDA) during pregnancy to HIV positive women decreases the risks of low birth weight (<2500 g), and pre-term birth (< 37 weeks gestation), compared to multivitamin supplements at doses above the RDA.
Condition | Intervention | Phase |
---|---|---|
HIV Infections |
Dietary Supplement: Multivitamins-Multiples of RDA Dietary Supplement: Multivitamins-Single RDA |
Phase 3 |
Study Type: | Interventional |
Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Prevention |
Official Title: | Comparison of Two Multivitamin Dosage Regimens in the Prevention of Adverse Pregnancy Outcomes Among HIV-Positive Women From Tanzania |
- Low birthweight (< 2500 g) [ Time Frame: Delivery ] [ Designated as safety issue: No ]
- Pre-term birth (< 36 weeks gestation) [ Time Frame: Monthly until the 32nd week of pregnancy, once every 2 weeks from 32nd to 36th week ] [ Designated as safety issue: No ]
Enrollment: | 1141 |
Study Start Date: | November 2002 |
Study Completion Date: | July 2005 |
Primary Completion Date: | July 2005 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Experimental: Multivitamins-Single RDA
Multivitamins at doses resembling a single daily Recommended Dietary Allowance (RDA)
|
Dietary Supplement: Multivitamins-Single RDA
1.4 mg B1, 1.4 mg B2, 1.9 mg B6, 50 mcg B12, 100 mg niacin, 70 mg C, 10 mg E, and 0.4 mg folic acid taken orally once per day until 6 weeks after delivery
|
Active Comparator: Multivitamins-Multiples of RDA
Multivitamin supplements at multiples of the Recommended Dietary Allowance (RDA)
|
Dietary Supplement: Multivitamins-Multiples of RDA
20 mg B1, 20 mg B2, 25 mg B6, 50 mcg B12, 100 mg niacin, 500 mg C, 30 mg E, 0.8 mg folic acid taken orally once per day until 6 weeks after delivery
|
Detailed Description:
This is a randomized clinical trial conducted to examine effects of daily administration of multivitamin supplements at doses resembling the Recommended Dietary Allowance (RDA) during pregnancy to HIV positive women decreases the risks of low birth weight (<2500 g), and pre-term birth (< 37 weeks gestation), compared to multivitamin supplements at doses above the RDA. All women receive standard prenatal care, including nevirapine for the prevention of mother-to-child transmission of HIV.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- HIV-positive pregnant women who are between 12 and 27 weeks gestation who intend to stay in Dar es Salaam until delivery.
United States, Massachusetts | |
Harvard School of Public Health | |
Boston, Massachusetts, United States, 02115 |
Principal Investigator: | Wafaie W. Fawzi, MD,DrPH | Harvard School of Public Health |
Publications:
Responsible Party: | Wafaie Fawzi MD, DrPH, Harvard School of Public health |
ClinicalTrials.gov Identifier: | NCT00197678 History of Changes |
Other Study ID Numbers: | HD32257-2 |
Study First Received: | September 13, 2005 |
Last Updated: | November 9, 2010 |
Health Authority: | United States: Institutional Review Board Tanzania: Institutional Review Board |
Keywords provided by Harvard School of Public Health:
HIV AIDS Multivitamins Pregnancy Outcomes |
Women Tanzania Africa |
Additional relevant MeSH terms:
HIV Infections Acquired Immunodeficiency Syndrome HIV Seropositivity Lentivirus Infections Retroviridae Infections RNA Virus Infections |
Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Slow Virus Diseases |
ClinicalTrials.gov processed this record on October 16, 2012